UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): November 13, 2013
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
Delaware | 1-1136 | 22-0790350 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrants telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) (c) On November 13, 2013, Bristol-Myers Squibb Company (the Company) announced that Giovanni Caforio, M.D., President, U.S., was promoted to Executive Vice President and Chief Commercial Officer, effective November 13, 2013. Dr. Caforio, 49, joined the Company in 2000 as Vice President and General Manager, Italy, in the Worldwide Medicines Group and has served in roles of increasing seniority. From 2007 through 2009, he served as Senior Vice President, U.S. Oncology, and from 2009 through 2010, he served as Senior Vice President, Oncology, Global Commercialization. In 2011, Dr. Caforio served as Senior Vice President, Oncology and Immunoscience, Global Commercialization, prior to being named President, U.S. There are no arrangements or understandings between Dr. Caforio and any other persons pursuant to which he was selected as an officer. There are no related party transactions between the Company and Dr. Caforio.
Effective November 13, 2013, and in connection with Dr. Caforios promotion to Executive Vice President and Chief Commercial Officer, Dr. Caforio will receive the following compensation:
| An annual base salary of $875,000; |
| An annual discretionary incentive payout under the Companys Senior Executive Performance Incentive Plan or any successor annual bonus plan based on a target bonus opportunity of 100% of his base salary based on the attainment of one or more pre-established performance goals established by the Board or a Board Committee; |
| Participation in the standard annual long-term incentive award program, including eligibility to receive grants of performance share units and market share units, the terms of which will be based on the Companys standard forms of equity award agreements under its 2012 Stock Award and Incentive Plan; and |
| Change-in-control and severance benefits in the event of involuntary termination without cause in the same form as provided to the Named Executive Officers of the Company. |
On November 13, 2013, the Company also announced that Beatrice Cazala, Executive Vice President, Commercial Operations in charge of Global Commercialization, Europe and China, will no longer serve as an executive officer of the Company and is in the process of transitioning to a new role within the Company.
A copy of the press release announcing these management changes is attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 | Press release dated November 13, 2013. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BRISTOL-MYERS SQUIBB COMPANY | ||||||
Dated: November 13, 2013 | By: | /s/ Sandra Leung | ||||
Name: | Sandra Leung | |||||
Title: | General Counsel and Corporate Secretary |
EXHIBIT INDEX
Exhibit |
Description | |
99.1 | Press release dated November 13, 2013. |
Exhibit 99.1
Bristol-Myers Squibb Announces Changes in Senior Management Team
(NEW YORK, November 13, 2013) Bristol-Myers Squibb Company (NYSE:BMY) today announced a series of related changes within its Senior Management Team. To support its ongoing success as a BioPharma leader, the company is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization.
Giovanni Caforio has been appointed executive vice president and chief commercial officer, a newly created position in which he will lead all of the companys commercial units across all geographies. Caforio will be responsible for the global commercial strategy of the company and for the performance of the companys commercial operations worldwide. Caforio was most recently president, U.S.
Charles Bancroft, executive vice president and chief financial officer, will take on an expanded role that includes the Business Development and Strategy groups. Bancroft will be responsible for developing an integrated approach to finance, business development and strategy that will enhance the companys effectiveness in meeting its long-term goals.
Caforio and Bancroft will continue to report to Lamberto Andreotti, chief executive officer, and will remain members of his Senior Management Team.
Murdo Gordon has been appointed president, U.S., and will report to Caforio. Gordon was most recently senior vice president, U.S. Oncology.
Beatrice Cazala, executive vice president, Commercial Operations in charge of Global Commercialization, Europe and China, is in the process of transitioning to a new role within the company.
By evolving our organization and expanding the roles of Giovanni and Charlie, I feel even more confident in the strength of my management team and our ability to take advantage of the most critical opportunities to build long-term sustainable growth, said Andreotti.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
###
Contacts
Media:
Laura Hortas, 609-252-4587, laura.hortas@bms.com
Investors:
John Elicker, 609-252-4611, john.elicker@bms.com
Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
Ryan Asay, 609-252-5020, ryan.asay@bms.com
2/<"K$$]*@GIV['0 M;T+FUQ[RC?:#QJT:RSE.U#4EFK3/4YNFVEI4;:\>$)Z+.&O)XK]JNW(.EDFJ MA`==TG:R:)_*H*@F4ZJOHMD3"5,A3**&[%*`F$`% UIM)BG+./%\JU>R4A)S,D ?E$5C&P'Z2S,Q[(BBI9CUH!I:<_P# `=V)P\8R]A;MXY=)=@R,5--,YW'JF*!TR`8#=-&2]L.0 MXW$W6;67'W&/LR/,;>YCF9"7V?4J&O GS.E'%>[7&,IFK3`^+(VN1O03" M+FUDA5P$W_2SBG8=AU![TZ:D%[AUGNM0[]M5UVNUR=YN]1S:I6"^WVQ0]1IE M3BG ?\5M\EC<4;GR7N M6VM;>-6970J65_(`%"$#O4GJ.G71GUG6:#AN>6G5-1G0K%$ID<,K8YP8^5E2 MQ[$IRI^K]OA64C)..ZBA2]DD3"'?N/8H"(`L1A[_`#V1BQ.*C,E_.VU%W`5^ M'ZB%'\S7\='LWF\=QS%S9G,R>''P*6=Z,U!^"@M_/M^&KX[J]-W/+J+L&>.W MCZD:+76-IJ[R0CW$4] 0S*7O%B M0!5Q*3"ABH,V#),L>N8AS=:O#Q1H,-;(NRYDE`F>(2"-/(P(02O^HK&E*1Q@ M%F>2LB_3K%)^8&ZSMVS^2TAB)MTE:,RN(U(+F)`2N^1ZDR2$[55`(VJ=!?8] M*JT-0:C#9[
ZD5H^%J6@01D6*2I//\` M:GZ+AH@93ZX`,`G,+A[J;(2RWZP6S7:,LRAM\$E:U8*"9(G)J.[(0S#]L=U[ M/YBTBQ\,.+DGN4LY`\#^/9<1;2"4+46.6,]R?H=-H-)".G,T'2="KNI1BVPU MR-I%FI$1+O:J\F4'EMS^HN-$MUHM:MECX"LJ.)>T65U'2XND&AEHU!`';4KA MT"K`I#?>_P`+CIL2T>&E$UK-+^Y0B.:3Q!4\>YEHL8*TW48DJ2J4D;5/$YG* MVV6A?.6XM[BW@_:)!FAB,S%]X56W.Y!W*OT!=P#N3&NC/:-3IU?JT^SHNN6# M2'D[8U-&>1UPICFO6B+U0KM&6;W7-[/#5R/AX9%*6:)">`D4%&CEF*K8'S,.&RMQC"Z MR>"0J''9E[J>P[J03TZ'IZ:U_C^5_P!\PUMEMC1&>,,4/=6[,.Y[,#3KU%#\ MM0_^[UW+R/\`:4433%8Z?,9(Y$2"0IUCD6I)RHD,H)2%.J8``!,(%`1`1'MU MLGLV2<#RP;J?]D/X?J(K\>E?3KK#O?0?]\XE(H)IFAT%*U'C-!7YC\/F-!W< M-`=;+[I'!]7E9G]GX;PV1R-ED\#);#Q-P= 2LZD)Y8JQ1+N1.C/W;:?UB MCD9;[C^U[=LVF91F/!F]2;7%-UC,@URS36N9[")TF,>B=-Q:3LP*^;SKYF=J MNX/'1[ER4C--,YW('7(F"1EO;3"8'`VF7RN=@1[_`![7-M&L$SF0C]*DD#8" M*#>ZCZZ@`@5T_8CW2Y%G^076&Q7';EX;#(BVN9&N85\8-07"]0S`@DHC$;*$ ML"U-!2#]QK$\$S'G?M%>XAAE4SE/*:(RR\UZ-EZE%R^JZS;%&< MP598HNG!SN78K2A2(]S%$RJHDZ.S>V>>Y#D\!A;O,?=6]YBFGC=A(P@MD)_; MB1B&9O@@"4->P%=+L'NIQ_C.&Y#R"VP?V X#R-Y-6_@9R[BI_CS`U&$#&*E/1FS9KO:-WSBQ4VY2D@VGI6E6 M=E2J^YF9>N*Q;5!S$B#91RUD@7(L9$2@I]?;SC/&+7W"P[07\DTOW >W68BGQ<,$0M(G2X@NQ+`\ Y@S7G)?Z32N(?&.M\?&UUY2:5B58LT#GS/68U"E5C&J MS3XAHUUK2M$&IJ&K:$ZJV.5"(;1L@[%8OI@H83$$XC+<#Q]]D 5[AY6_8@AW@-MJ-SLZ*!U([T,X;W!RF.Q6"XG:XU;GF%UCXG6$7* MB-+9(E`N)Y=A*;Z,0@1B2*;JD`[>\\S76E4/G%Q6V+,%L1Y(9KQ:TZ]*55"V M,[Y3;[G +@%Y1BV=."(O6CI@U=-%#>4Q3>4_DJV7"TQE]@^7 M82Y%]QJZRL,(D*&*2*99%)BFC+,`U`64JS*1U!ZBMC(\ZDR^*S_"\]9G'\KM M<3/,8A*)HI86C:DL,H"DKU`(9%(-1UVM0X>U+X^W)P\^??%*U_S.NA/NV:>Y MF:![_?/_`$:9O9T?_P`QPG_TE_YG4?GNV\;7W*SE/QLRFO2#N(T%MQIY2Z!D MTPR=*-%XO5:!+9-8:8L"Z9TQ3(\?M1:F.(_X0+^H'ZB!T]^T?*5XCQO(Y2=0 M^.DR5E!<*14-;RK.LHH>G1?J`/0TH>^LO]Z^)R 33%7L]LP)6E MQ"\3Q]1U`8C:2.HK7TT-'/+B4]R_BI2<(<)O8FT53+=,TCGW%)).HUQ`'P2+ M?,:U0'@>9$6W^M&I,6;\[PPXIJAE M;[EP6E'?=]O"62O9F8'X:`W'.)O=CA<7'*O'>06-Q<9<`%63[-&$<=/0W,ZJ MY4]552NM![=?,V?XC>W-P?%]C1[Q0=DUVVY2OI1]$CJA"9]=+9JUI0ADK>S> MUV67;P+YLDJH5\F<2`HF*1B%$Q#'\^Y/"X^9^YW(#%>+!D+*U2X\/C+-+'%; MQE]A#`;@>ZD=C77OVQYW-P?VLP(>P-QC;V\DM_,)0JQ227+A1(I1B%I4[J@5 M!!ZZE:Y(^X'&<7]#TR%O^8JN 8UU(-2VV;>5"CT-M0%85)X MM=[M **)ID$@Y)QKV_FY38VTF/N0,I=WK6\<+1L!]"AY) M3)4@11H07;:2"0H!)&MCY1[E0\2RMU;9*TKA[.R6XDN%F7*QCBA$14'RRR M`A`6`*@L2`#K@H;W#-.K>N<>\PY`<6G.9* (?M'6(32+.C,0<*UG4Z MGIM:_;U6)3Y&18OVY/KDG3R+:N51377(5-50A2X]M\7-A\CE.X6:2JA6" M3Q[8Q$Q#*-P=U5C]3`*Y45YG[LND:93;[K\=P=T5IA>/V78H#8=!4T^CN)"G M#D]?>3:B495$6WUUODWIF@-G1&2GTC-PX2*5PN'G,4QD_:'%8N\ML+)GK9L] M?1VS6\0ADVO]PZK] , MM&((V?Z8Z5D;Z:/M.U20`S:8;B7S5U_DP./6MUQU@(;%]KJ%FM,+J6?[,RU1 MK1).&:1\A'4/5(EK3*Z-5MLBV<+$.!'#E!)TB+<3>IX=+/,.$X7C`O+- Y_PVMO-3CBUI.:VAC4]6SC0*YK^8NYGS!7Y& MW5%O)MVL)-J`DN#-K(MI-3TG`I*E0 UO-;/@W)C>Y6$S8>YMW MMI@OZQ')2K+VZBG:HJ*^M->O=W@M]SSBXLL1*(LW:W"7,&XT1G0$!&^&X'H2 M"`:5Z:6?B+SUAN06IU?BCSWQ)AC/-W'Y KXY"C5>)'; M_2G0$;E#4%64,#3>JGJ5/A7N39\ES$'#? H4R85[?VGQMMEK#C&>RPM>6Y!8RL*6YE M2+R?Z:SRAUVNWH%1@O0D[2";%Q[PY:ZQ.1Y3QW#?=*NH&8Y1\9QY$%OC.SQRE2C$4JN M2?=5VO0G9]8I`S%Z;Z1==^,>(&`#ID5(;N`C->VL6-PN8SUO>*\&+R8M#&4( MD8[@N]CT4`@AAMW^H;:::,]TI\QFL+@KBP:.?+8PWGF$@,:C:S;%7JYH4* ML7V=P5#`ZX^U^X!6-+R#W%&FB\3I^S5+B`_-1-(RV?L]%EG&CP3R%D)*P/9- M!95:LQD*Q8,_7,FBZE')VX@=-,5@]+JW9^WMSC,QQHXS+QQ7F942Q3(DJ>!Q M($4`BDA Q'H.79A#U2/L#FYVFB9!%RK.&@()*1Q>"?PM+:S2 M<2DRCXYD51-M]45EV*0OG](1_3TYY3#6<<, @#;>PKMTR M6K\TI^_TSGWQ!VS)D,=W?/>(>FZ9%MH"\)Z)1]!SB;H4VV&=K-D4KU3DTWL0 M[=$0=M'#`@E,)A*80(8`4\=PNVQ]U@.986[:\P%QEX8&W1>&6&9)D;8Z!Y!1 MEHRL'(I\SIJS'/KO)67(N$ $M9#B_*TC'LZF=?K>F-WMUJKVW,"I,;5+Y@O5&J'[ M2;R7F;*BE,J.RB4#BF'G(06+E/![#F7N%G[#'7S+RE+BXF2!X?VI!&:LBSAR M?)MJPK%M(]>^@'$^?9'@WMMQW(Y;'!N)O;6\+W*3J98S(O1V@\8'CW#;42[Z MD=*G4[?[QJ?_`-)"?^S;_P"9U@?V&0_]J7_I/]6OT#_NV(_^1%_U?VZ2B=P> M&HFSV"0HJL507VQ.9&YP;UU6V-AH\_H$8U%Y *D\%-%T:RQK49F/?,%8Z M6(=*1*#DZ29$3.L'([N[PL<-V9)H;)0C!9&61(B?VY(G'JI)1E; 0R3IC['>AEDD+2SR%:!!UVHIJ?I05JR!V-00I9JP3/VM MC93Q0293(>-Q#'$JPV\88DNW0NYZ$AF/14=E3H01SFF)UO&[C1+"[DIB(K^J M2%]HD5JI_HY2P56X5K3[A'1C6T)3K22@+#5Y-0?5,RDT%4"(OG`H"W(P(8+V M0Y+D,SCKBW0CSVC)(UN*HKQM$E638RN)%[50@U`W;VEZ#<3Q>PP.1M+N8MX+ MX-$MRP#O'*LC`*ZNI0QL>M&!`5B%VK%4LU88&T:5#R]/M+RDDF7^C6+$:K4< M[J"=3C[7(5X@+6'4+]**N9*QH5^O5[UY)2"8.6[$ZZ"+5=P\!R0A5R*\7%RQ MWUF]SXA:I TC MBAA6-9"@!>>5OJ<*D=6,:LJ;@JM7 L[R&0N\MD)LE?N9+V:0L[&O4 MGKZD]!V'H!0#MK4L7C;/#XZ'%X]%2R@C"H!\!ZGH!4GJ3ZDDGOJ'?W8\XY%7 M#9N!FB9/Q[N6QT+CKM*.M:`^H$K7G=I(DC*5XJT!&TV2?1LD] L,UD8;*_R-C]O")0X2IJ=[2`%5`/2C4[UZ]M8 M;[UXWE-[F./Y#"8N>_QN-OON)C"RF3H4&Q8JAF)`)!`I7H:=]Y-O MW$.'K?'C7L/POCKJ;;:M(U;=H&.H-AEWL6XBG3.DY]2RR\G8Y)X\)%BFHZ4( MBV!54IN_D1[J7N(9'!^V&`S$]UD;.^S^1M3;PP6K&5`&W@R32;0BTJ"`#NI7 MU-`,YGC.0^['),)#:XN_Q_',9=? 63`+ .KC<]:V64Q6$\:S(S@)=HX94=ME?&RLREQNZCJ"M043"6>>QB\ MB7)< C`BH$<+PXY"-.._N>Y)Q_S M'>*OQ4T;+X(.,F%;B8K"^%U`KIC,WQM0Z[+RTA-0M5.BT.V;`]524D%00[>H M ;<>;DG%\SR.YL).76]S(+VZMOJC,!5EC\TB`*\M34[`0JUJ1VT(MN M#\E3C?*\1QVSR47#KF"/[*TNA27SAXWE\,;,76.@8#<06(!&X]=&K-Z9O><\ MC.-?.B.XM;[)4>.XK5WB)MN8/J[76VUU.1J,5#NF&G5+/RV=P]L=(>2S7Z-1 M(%$)+L@HN5L*9TQ,&RF0X_DN-Y?@,N4L!?/EWR%KXB8?)M9)A8\;=6Y1/NHS$@I.D._ /XC@\>0M)[XYJ._NYU+&W@2,KMC M67;^XY"@DHI%:K4^MK)X/DG)^1YKGSXV]M[/_8Y9V[HHN;AI%<&5HMU8T# M2,`'8&FTT[@'GBGP1HFQ\+^*E(Y39CL='T7!\Z4S=[73:3?LO<-W:3E)Q)/" MM\RO4?&V&+>J)IBU=KF.H!2F``)^H!" :W()-6Z0R*K`]*$]?3 M7KG 3<]>&,?EV`[G-X-@N,:WD\EHX.$+A"Q;W7G5-?0#AQ9;?=G-TGHZ" M4@W`2SM \>LII 5XFC`0,5"J&8N14=2S M=2::CDXE\2;1;?9WOW#?DQF]NPFTT^#T&2"Q:&C!,HB*G2V":TFF7^NS49-2 M@?;JN\0;G?K*@V41\JA.QB&$PZ5RWE]K9^]4/,^+W,60L[B:%=D&\LZ>-(98 M61E6ID&X*.H8T/?67<.X;=WOL;<<+Y9:S8^\MTGU':K1:9"*>\L.1JF4[6T&14%A$3T-C;"$@\CISEVZ-Z; M5M9J1!'DP74\J/W2<464\A3F$MF3F?&N&>[45O:(Z\0QXGMFVU9U-UO-S)\V M1W\?:I2)0*D#5*VX/R;FWLU+=WCJ_,LDT%T":*)$M0JVL1J0`'B7R#J`'E)) M`).FLXS2KV"MB.C-^"G)XO(ZY"FKO.H[\O$KEH-7CVYW$[4,BNC^ E(88%`;=]9 M`ZZX#@-"\C>/W#+EM&R7&"\N-42V;;-AHF5Z$QBV$?J]=T*10D(FL,'<5*SR M*DN^BF2[=RV5(!$G"J13> P)` M-0=<1Q,X\VZA>X!7]*XLX'OO%/C);,WM;[E5E>N,&=:S5SI+ANJ2GM,KKQ9^ M<2D9=K+JE6<.XS_QK9ND8J*A4UC(=%>9 RXWEN0QV6Y3# <-K36>+^S\=Z%QLLTU==*VW E8JJJ:$=*U*BAZT`RCDV)SGNCS;"7=KA[_`!EAC6D:XN[M M%ADVMM(BB4,YD%0?EN8GH*D@NJP&P\1?;1Y@<)-:P'6TY.KU7DJ^K6X5N"AY M?#K)0K)'S-EA[6^NGWYLXB7P^L9LK'':'?D4%,`3,'G$C!/=83F'NIA. *0,XD:7?0'N-E"U*5`-:=7FM*V&AV+VAN8%4Q31=MR^@\&RY/?8O(V<+ M-7BMR=PI$:I!S`5N8F8,9")6.Z\JBB:P`EZ9_,(#Y`-2R5_AK^SY?PFZOK:R MRLV;-Q$TY98I%CDHRAE5J-]/2HZU%*]:7\199S'7'#.<6./NLAAX,"MO*ML% M>5&=&HVPLH*U<=:B@#5/05\$-FG)Y>@>\8VLG$W;("R\QGKB 3;K2)/,9)L4%@(HJ*78WSGRG%ER/"VM,M9RVF' M"K Y`^MED.,WD_-;,9>PBFS+G[4R,Z1LO MF,P9I#'M6H(6A-:]Q3KKS=6'+,?;\&NSA,C+!A($%T(T1Y498TB(6,/N8="P M["G2M==[?\/Y' K5'6M#?7%HX2LMYF8 M*0G#Q]5A8AS)*F;-GSM-\\2+V(F!^Q1%V. _%WVYV7%W;\LML#(Y7"[GJ&L5Z*JN8T> MG9I+'DIB9KU@";=NKM*3GTR`L&C!L8_ -<6]QLI[F-E+&YM) M5N'M8(',D\DEPI4*Z[0(MFX[BQ`K3;4:!/AN4\L]L,1[5Q8;(VEY&\"7<]Q& M(K>*.!MQ=&))E+D#:JK7O7TK//\`_FK/_P#KS7_>%_RNL(_\SS7^3_I_MU^@ M/_`L)_BD_P"(_JUTFX1]?E*(>.FIX:Q)NYR!1HM@;,G4E)Q.BFD4AICR*CV3 M5X^>K)2@%^H233$IX_Z@%1*AZI@$X1[B&^$D*>6-8V\JDA0T5/W-Q)``VUH2 M>C4I4TT:Y'':38PQ74@BD:1/"]"Q6:O[155!8FO<`?IW5H*G407'9;8&UWGH MB;:2+VSMLKI8IVG)#12UKF PH3]3(G4ABRA*8AQ1L]'DY MH+I9'O5M4_=M]OD>`!:BW69D\:FJ]55Y/I%`KEZ]1I<_$O./-GDLJHVH1.4G MF7#)&L:_),5ZT-_3E9$SN6HT]8;$\T>'L:MC*^"9^F1EXM4PO2.&S &B* MXA%0,]4I))^YL(56)6&F[Q`]*E^I-=,WMW!,D]Q-G)@^;=Y"(Z./$G[?D!9E M"O,6V^8J2:!?0ZD<+\/R^7\OE\NLY%?7^/CK6!2G3M35Q_W#UQ[_`#U)U@/; MOX]OA^?QZ\]*C=6M?S^6O/2M!WIZ:KL'8>XA\>I-.N_]/S_MU)!IUK3Y:H.W MAXAW[_Q\N_4TZ&I^G\M0-M?0'^.VK#\?[OQ_/N`]>:+M[BGIKAW-*5]?X_#6 M0?$>W;M_3WZZ@KT/7\M2:UZT_IUB/;OX"`#_`+>W4G]/7M7\]W\?GJ!3N.U?SU M8>WF#Q#X#V#Q^/S'^74=*C_'Z?VZG\.W]/\`'PTFW/RJ9E<>*NF1.VZ??,EQ M5-K%2.MVC.(*3L$^YH#"5:+3M?=LH2KW"=0K$V3R)2R[-F*J4?ZHG431]4X. MOM]=96SY9:S8.VM[O-$L+>.5E11,5(1PS/&F]#UC#&A>E`30:1/ 7%E@J*;F2!&=C"#]:$*DCA&'1RJU"UZ@5TU51"N?M.L_L\8\:C^WX7]J MC$@'VS]M_;6WV/[=Y?T_0C&>EZ/;P]/MTJ7GW/W (?'P\!_J^'X=>6V[3N^5:_Q_P`-20=W4_5_:*Z^GAV\ M1+_4';MUZ:E33OZZX>G;Y4_HUB(!X=Q_GX#^74"G0]:=*=]30U%#]?\`1ZZN M/;L/C^'AX_T`/Y=21U[BO\M0U/7^/QII5^;57H]QXK[=`ZAIEAR/+'5$G#:A M>*K`H62 F_@%UD++E]A<8 M:VBO,P+E?!%(VQ&FK^W5BZ#HU#]3!2>_327[BV>,O^$Y&VS=W)8X1K5_N)HT M$C+``?)1=DE25J/I0L/[HKKU\,ZS3:AQ=P^!S?1Y_5\Q9YU6?],;Q:(-O79V M6SI6+;*4P'T4A7ZNLB9K`BBF!G+%N\.4`% 8>JW-KF[O.4WUQDK:.TR#7 M#^:)'+JL^[]RC%G!JU2-K$#^Z::^GM_9V-CPS'VN*NY;W#K;)X)I$$;/#3]O M WAV_+MW[]+!Z,?4UZ_CIQ]>E*T_+^/AK/Y_B/\?AUZ MH?CKQTK_`)M5X>/\_P`_CU'T]:?EWU[%?2M=8AV[_$O;N/R'OW^?QZD5Z]J^ =OQ_GJ!MJ/\7I\?GJ_8/Q_L_X=17Y?GJ*-\3K_]D_ ` end